Pancreatic cancer: Proteomic approaches to a challenging disease

Pancreatology

Volumn 9, Issue 5, 2009, Pages 567-576

  Tonack, Sarah ^a   Aspinall O'Dea, Mark ^a   Neoptolemos, John P ^a   Costello, Eithne ^a  

^a ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Affinity chromatography; Biomarker; Pancreatic cancer; Proteomics

Indexed keywords

ALBUMIN; ANTITHROMBIN III; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; AUTOANTIBODY; CALGRANULIN A; CALGRANULIN B; GAMMA INTERFERON; IMMUNOGLOBULIN; INTERFERON; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 8; LIPOCORTIN 2; PREALBUMIN; PRORENIN; SMAD4 PROTEIN; SOMATOMEDIN BINDING PROTEIN 2; T BOX TRANSCRIPTION FACTOR; T BOX TRANSCRIPTION FACTOR TBX4; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKER; UNCLASSIFIED DRUG;

AFFINITY CHROMATOGRAPHY; AMINO TERMINAL SEQUENCE; ANTIGEN BINDING; BLOOD ANALYSIS; CANCER CELL; CANCER DIAGNOSIS; CANCER RESEARCH; CANCER TISSUE; CARCINOGENESIS; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEAVY CHAIN; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOAFFINITY CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MICRODISSECTION; NONHUMAN; PANCREAS CANCER; PANCREAS JUICE; PLASMA; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN MICROARRAY; PROTEOMICS; REVERSED PHASE LIQUID CHROMATOGRAPHY; REVIEW; SEROLOGY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TANDEM MASS SPECTROMETRY; TRANSGENIC MOUSE; TWO DIMENSIONAL GEL ELECTROPHORESIS; URINALYSIS; WESTERN BLOTTING;

EID: 68049111322     PISSN: 14243903     EISSN: 14243911     Source Type: Journal    
DOI: 10.1159/000212083     Document Type: Article

References (67)

1. Ghaneh P, Costello E, Neoptolemos JP: Biology and management of pancreatic cancer. Gut 2007; 56: 1134-1152.
2. Aspinall-O'Dea M, Costello E: The pancreatic cancer proteome - recent advances and future promise. Proteomics Clin Appl 2007; 1: 1066-1079.
3. Chen R, Pan S, Aebersold R, Brentnall TA: Proteomics studies of pancreatic cancer. Proteomics Clin Appl 2007; 1: 1582-1591.
4. Loperfido S, Angelini G, Benedetti G, Chilovi F, Costan F, De Berardinis F, De Bernardin M, Ederle A, Fina P, Fratton A: Major early complications from diagnostic and therapeutic ERCP: A prospective multicenter study. Gastrointest Endosc 1998; 48: 1-10.
5. Suissa A, Yassin K, Lavy A, Lachter J, Chermech I, Karban A, Tamir A, Eliakim R: Outcome and early complications of ERCP: A prospective single-center study. Hepatogastroenterology 2005; 52: 352-355.
6. Vandervoort J, Soetikno RM, Tham TC, Wong RC, Ferrari AP Jr, Montes H, Roston AD, Slivka A, Lichtenstein DR, Ruymann FW, Van Dam J, Hughes M, Carr-Locke DL: Risk factors for complications after performance of ERCP. Gastrointest Endosc 2002; 56: 652-656.
7. Crnogorac-Jurcevic T, Gangeswaran R, Bhakta V, Capurso G, Lattimore S, Akada M, Sunamura M, Prime W, Campbell F, Brentnall TA, Costello E, Neoptolemos J, Lemoine NR: Proteomic analysis of chronic pancreatitis and pancreatic adenocarcinoma. Gastroenterology 2005; 129: 1454-1463. (Pubitemid 41597388)
8. Shekouh A, Thompson C, Prime W, Campbell F, Hamlett J, Herrington C, Lemoine N, Crnogorac-Jurcevic T, Büchler M, Friess H, Neoptolemos J, Pennington S, Costello E: Application of laser capture microdissection combined with two-dimensional electrophoresis for the discovery of differentially regulated proteins in pancreatic ductal adenocarcinoma. Proteomics 2003; 3: 1988-2001.
9. Rai AJ, Vitzthum F: Effects of preanalytical variables on peptide and protein measurements in human serum and plasma: implications for clinical proteomics. Expert Rev Proteomics 2006; 3: 409-426.
10. Hustinx SR, Cao D, Maitra A, Sato N, Martin ST, Sudhir D, Iacobuzio-Donahue C, Cameron JL, Yeo CJ, Kern SE, Goggins M, Mollenhauer J, Pandey A, Hruban RH: Differentially expressed genes in pancreatic ductal adenocarcinomas identified through serial analysis of gene expression. Cancer Biol Ther 2004; 3: 1254-1261. (Pubitemid 41350962)
11. Gygi SP, Rochon Y, Franza BR, Aebersold R: Correlation between protein and MRNA abundance in yeast. Mol Cell Biol 1999; 19: 1720-1730.
12. Tian Q, Stepaniants SB, Mao M, Weng L, Feetham MC, Doyle MJ, Yi EC, Dai H, Thorsson V, Eng J, Goodlett D, Berger JP, Gunter B, Linseley PS, Stoughton RB, Aebersold R, Collins SJ, Hanlon WA, Hood LE: Integrated genomic and proteomic analyses of gene expression in mammalian cells. Mol Cell Proteomics 2004; 3: 960-969.
13. Patton WF: Detection technologies in proteome analysis. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 771: 3-31.
14. Unlu M, Morgan ME, Minden JS: Difference gel electrophoresis: A single gel method for detecting changes in protein extracts. Electrophoresis 1997; 18: 2071-2077.
15. Harris LR, Churchward MA, Butt RH, Coorssen JR: Assessing detection methods for gel-based proteomic analyses. J Proteome Res 2007; 6: 1418-1425.
16. Berggren K, Chernokalskaya E, Steinberg TH, Kemper C, Lopez MF, Diwu Z, Haugland RP, Patton WF: Background-free, high sensitivity staining of proteins in one- and two-dimensional sodium dodecyl sulfatepolyacrylamide gels using a luminescent ruthenium complex. Electrophoresis 2000; 21: 2509-2521.
17. Qi T, Han J, Cui Y, Zong M, Liu X, Zhu B: Comparative proteomic analysis for the detection of biomarkers in pancreatic ductal adenocarcinomas. J Clin Pathol 2008; 61: 49-58.
18. Sheikh AA, Vimalachandran D, Thompson CC, Jenkins RE, Nedjadi T, Shekouh A, Campbell F, Dodson A, Prime W, Crnogorac- Jurcevic T, Lemoine NR, Costello E: The expression of s100a8 in pancreatic cancerassociated monocytes is associated with the smad4 status of pancreatic cancer cells. Proteomics 2007; 7: 1929-1940.
19. Marouga R, David S, Hawkins E: The development of the DIGE system: 2D fluorescence difference gel analysis technology. Anal Bioanal Chem 2005; 382: 669-678.
20. Minden J: Comparative proteomics and difference gel electrophoresis. Biotechniques 2007; 43: 739, 741, 743 passim.
21. Link AJ, Eng J, Schieltz DM, Carmack E, Mize GJ, Morris DR, Garvik BM, Yates JR: Direct analysis of protein complexes using mass spectrometry. Nat Biotech 1999; 17: 676-682.
22. Liu H, Lin D, Yates JR 3rd: Multidimensional separations for protein/peptide analysis in the post-genomic era. Biotechniques 2002; 32: 898, 900, 902 passim.
23. Florens L, Washburn MP, Raine JD, Anthony RM, Grainger M, Haynes JD, Moch JK, Muster N, Sacci JB, Tabb DL, Witney AA, Wolters D, Wu Y, Gardner MJ, Holder AA, Sinden RE, Yates JR, Carucci DJ: A proteomic view of the Plasmodium falciparum life cycle. Nature 2002; 419: 520-526.
24. Gao J, Opiteck GJ, Friedrichs MS, Dongre AR, Hefta SA: Changes in the protein expression of yeast as a function of carbon source. J Proteome Res 2003; 2: 643-649.
25. Liu H, Sadygov RG, Yates JR: A model for random sampling and estimation of relative protein abundance in shotgun proteomics. Anal Chem 2004; 76: 4193-4201.
26. Ishihama Y, Oda Y, Tabata T, Sato T, Nagasu T, Rappsilber J, Mann M: Exponentially modified protein abundance index (EMPAI) for estimation of absolute protein amount in proteomics by the number of sequenced peptides per protein. Mol Cell Proteomics 2005; 4: 1265-1272.
27. Bridges SM, Magee GB, Wang N, Williams WP, Burgess SC, Nanduri B: Protquant: A tool for the label-free quantification of Mud- PIT proteomics data. BMC Bioinformatics 2007; 8(suppl 7):S24.
28. Patton WF, Schulenberg B, Steinberg TH: Two-dimensional gel electrophoresis; better than a poke in the ICAT? Curr Opin Biotechnol 2002; 13: 321-328.
29. Chen R, Brentnall TA, Pan S, Cooke K, Moyes KW, Lane Z, Crispin DA, Goodlett DR, Aebersold R, Bronner MP: Quantitative proteomics analysis reveals that proteins differentially expressed in chronic pancreatitis are also frequently involved in pancreatic cancer. Mol Cell Proteomics 2007; 6: 1331-1342.
30. Chen R, Pan S, Cooke K, Moyes KW, Bronner MP, Goodlett DR, Aebersold R, Brentnall TA: Comparison of pancreas juice proteins from cancer versus pancreatitis using quantitative proteomic analysis. Pancreas 2007; 34: 70-79.
31. Chen R, Pan S, Yi EC, Donohoe S, Bronner MP, Potter JD, Goodlett DR, Aebersold R, Brentnall TA: Quantitative proteomic profiling of pancreatic cancer juice. Proteomics 2006; 6: 3871-3879.
32. Wu WW, Wang G, Baek SJ, Shen RF: Comparative study of three proteomic quantitative methods, DIGE, CICAT, and iTRAQ, using 2D gel- or LC-MALDI TOF/TOF. J Proteome Res 2006; 5: 651-658.
33. Shadforth I, Dunkley T, Lilley K, Bessant C: i-Tracker: For quantitative proteomics using iTRAQ. BMC Genomics 2005; 6: 145.
34. Pierce A, Unwin RD, Evans CA, Griffiths S, Carney L, Zhang L, Jaworska E, Lee CF, Blinco D, Okoniewski MJ, Miller CJ, Bitton DA, Spooncer E, Whetton AD: Eight-channel iTRAQ enables comparison of the activity of six leukaemogenic tyrosine kinases. Mol Cell Proteomics 2008; 7: 853-863.
35. Tang N, Tornatore P, Weinberger SR: Current developments in SELDI affinity technology. Mass Spectrom Rev 2004; 23: 34-44.
36. James P: Chips for proteomics: A new tool or just hype? Biotechniques 2002;suppl:4-10, 12-13.
37. Ehmann M, Felix K, Hartmann D, Schnolzer M, Nees M, Vorderwulbecke S, Bogumil R, Büchler MW, Friess H: Identification of potential markers for the detection of pancreatic cancer through comparative serum protein expression profiling. Pancreas 2007; 34: 205-214.
38. McDonald L, Robertson DH, Hurst JL, Beynon RJ: Positional proteomics: selective recovery and analysis of N-terminal proteolytic peptides. Nat Methods 2005; 2: 955-957.
39. McDonald L, Beynon RJ: Positional proteomics: Preparation of amino-terminal peptides as a strategy for proteome simplification and characterization. Nat Protoc 2006; 1: 1790-1798.
40. Faca VM, Song KS, Wang H, Zhang Q, Krasnoselsky AL, Newcomb LF, Plentz RR, Gurumurthy S, Redston MS, Pitteri SJ, Pereira- Faca SR, Ireton RC, Katayama H, Glukhova V, Phanstiel D, Brenner DE, Anderson MA, Misek D, Scholler N, Urban ND, Barnett MJ, Edelstein C, Goodman GE, Thornquist MD, McIntosh MW, DePinho RA, Bardeesy N, Hanash SM: A mouse to human search for plasma proteome changes associated with pancreatic tumor development. PLoS Med 2008; 5:e123.
41. Sahin U, Tureci O, Schmitt H, Cochlovius B, Johannes T, Schmits R, Stenner F, Luo G, Schobert I, Pfreundschuh M: Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 1995; 92: 11810-11813.
42. Hong SH, Misek DE, Wang H, Puravs E, Giordano TJ, Greenson JK, Brenner DE, Simeone DM, Logsdon CD, Hanash SM: An autoantibody-mediated immune response to calreticulin isoforms in pancreatic cancer. Cancer Res 2004; 64: 5504-5510.
43. Tomaino B, Cappello P, Capello M, Fredolini C, Ponzetto A, Novarino A, Ciuffreda L, Bertetto O, De Angelis C, Gaia E, Salacone P, Milella M, Nistico P, Alessio M, Chiarle R, Giuffrida MG, Giovarelli M, Novelli F: Autoantibody signature in human ductal pancreatic adenocarcinoma. J Proteome Res 2007; 6: 4025-4031.
44. Kusnezow W, Banzon V, Schroder C, Schaal R, Hoheisel JD, Ruffer S, Luft P, Duschl A, Syagailo YV: Antibody microarray-based profiling of complex specimens: systematic evaluation of labeling strategies. Proteomics 2007; 7: 1786-1799.
45. Carlsson A, Wingren C, Ingvarsson J, Ellmark P, Baldertorp B, Ferno M, Olsson H, Borrebaeck CA: Serum proteome profiling of metastatic breast cancer using recombinant antibody microarrays. Eur J Cancer 2008; 44: 472-480.
46. Orchekowski R, Hamelinck D, Li L, Gliwa E, VanBrocklin M, Marrero JA, Vande Woude GF, Feng Z, Brand R, Haab BB: Antibody microarray profiling reveals individual and combined serum proteins associated with pancreatic cancer. Cancer Res 2005; 65: 11193-11202.
47. Hudson ME, Pozdnyakova I, Haines K, Mor G, Snyder M: Identification of differentially expressed proteins in ovarian cancer using high-density protein microarrays. Proc Natl Acad Sci USA 2007; 104: 17494-17499.
48. Miribel L, Gianazza E, Arnaud P: The use of dye-ligand affinity chromatography for the purification of non-enzymatic human plasma proteins. J Biochem Biophys Methods 1988; 16: 1-15.
49. Thompson ST, Cass KH, Stellwagen E: Blue dextran-Sepharose: An affinity column for the dinucleotide fold in proteins. Proc Natl Acad Sci USA 1975; 72: 669-672.
50. Biellmann JF, Samama JP, Branden CI, Eklund H: X-ray studies of the binding of Cibacron Blue F3GA to liver alcohol dehydrogenase. Eur J Biochem 1979; 102: 107-110.
51. Gianazza E, Arnaud P: Chromatography of plasma proteins on immobilized Cibacron Blue F3GA. Mechanism of the molecular interaction. Biochem J 1982; 203: 637-641. (Pubitemid 12018128)
52. Gianazza E, Arnaud P: A general method for fractionation of plasma proteins. Dye-ligand affinity chromatography on immobilized Cibacron Blue F3-GA. Biochem J 1982; 201: 129-136. (Pubitemid 12038473)
53. Atlas SA, Hesson TE, Sealey JE, Dharmgrongartama B, Laragh JH, Ruddy MC, Aurell M: Characterization of inactive renin ('prorenin') from renin-secreting tumors of nonrenal origin. Similarity to inactive renin from kidney and normal plasma. J Clin Invest 1984; 73: 437-447.
54. Linke T, Ross AC, Harrison EH: Profiling of rat plasma by surface-enhanced laser desorption/ ionization time-of-flight mass spectrometry, a novel tool for biomarker discovery in nutrition research. J Chromatogr A 2004; 1043: 65-71.
55. Pieper R, Gatlin CL, Makusky AJ, Russo PS, Schatz CR, Miller SS, Su Q, McGrath AM, Estock MA, Parmar PP, Zhao M, Huang ST, Zhou J, Wang F, Esquer-Blasco R, Anderson NL, Taylor J, Steiner S: The human serum proteome: display of nearly 3,700 chromatographically separated protein spots on twodimensional electrophoresis gels and identification of 325 distinct proteins. Proteomics 2003; 3: 1345-1364.
56. Wang Y, Cheng P, Chan D: A simple affinity spin tube filter method for removing highabundant common proteins or enriching low-abundant biomarkers for serum proteomic analysis. Proteomics 2003; 3: 243-248.
57. Govorukhina NI, Keizer-Gunnink A, van der Zee AG, De Jong S, De Bruijn HW, Bischoff R: Sample preparation of human serum for the analysis of tumor markers: Comparison of different approaches for albumin and-globulin depletion. J Chromatogr A 2003; 1009: 171-178.
58. Omenn GS: The human proteome organization plasma proteome project pilot phase: reference specimens, technology platform comparisons, and standardized data submissions and analyses. Proteomics 2004; 4: 1235-1240.
59. Greenough C, Jenkins R, Kitteringham N, Pirmohamed M, Park B, Pennington S: A method for the rapid depletion of albumin and immunoglobulin from human plasma. Proteomics 2004; 4: 3107-3111.
60. Sun ZL, Zhu Y, Wang FQ, Chen R, Peng T, Fan ZN, Xu ZK, Miao Y: Serum proteomicbased analysis of pancreatic carcinoma for the identification of potential cancer biomarkers. Biochim Biophys Acta 2007; 1774: 764-771.
61. Whiteaker JR, Zhang H, Eng JK, Fang R, Piening BD, Feng LC, Lorentzen TD, Schoenherr RM, Keane JF, Holzman T, Fitzgibbon M, Lin CW, Zhang H, Cooke K, Liu T, Camp DG, Anderson L, Watts J, Smith RD, McIntosh MW, Paulovich AG: Head-to-head comparison of serum fractionation techniques. J Proteome Res 2007; 6: 828-836.
62. Gong Y, Li X, Yang B, Ying W, Li D, Zhang Y, Dai S, Cai Y, Wang J, He F, Qian X: Different immunoaffinity fractionation strategies to characterize the human plasma proteome. J Proteome Res 2006; 5: 1379-1387.
63. Brand J, Haslberger T, Zolg W, Pestlin G, Palme S: Depletion efficiency and recovery of trace markers from a multiparameter immunodepletion column. Proteomics 2006; 6: 3236-3242.
64. Yu KH, Rustgi AK, Blair IA: Characterization of proteins in human pancreatic cancer serum using differential gel electrophoresis and tandem mass spectrometry. J Proteome Res 2005; 4: 1742-1751.
65. Dekker LJ, Bosman J, Burgers PC, van Rijswijk A, Freije R, Luider T, Bischoff R: Depletion of high-abundance proteins from serum by immunoaffinity chromatography: A MALDI-FT-MS study. J Chromatogr B 2007; 847: 65-69.
66. Lin Y, Goedegebuure PS, Tan MC, Gross J, Malone JP, Feng S, Larson J, Phommaly C, Trinkaus K, Townsend RR, Linehan DC: Proteins associated with disease and clinical course in pancreas cancer: A proteomic analysis of plasma in surgical patients. J Proteome Res 2006; 5: 2169-2176.
67. Liu T, Qian WJ, Mottaz HM, Gritsenko MA, Norbeck AD, Moore RJ, Purvine SO, Camp DG 2nd, Smith RD: Evaluation of multiprotein immunoaffinity subtraction for plasma proteomics and candidate biomarker discovery using mass spectrometry. Mol Cell Proteomics 2006; 5: 2167-2174.